Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematological disorders, cancer and rare immune diseases.

Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

View Press Release View All

Feb 28, 2023 • 8:05am EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update

Feb 2, 2023 • 4:05pm EST

Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances

Jan 18, 2023 • 8:05am EST

National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

January 2023

View Presentation

Fourth Quarter and Full Year 2022 Financial Results

View Event View All

FY 2022

Fiscal Year Ended Dec 31, 2022

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-K

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
611 Gateway Blvd
Suite 900
South San Francisco, CA 94080